The ability to degrade extracellular matrix is critical for tumor cells to invade and metastasize. Recent studies show that tumor cells use specialized actin-based membrane protrusions termed invadopodia to perform matrix degradation. Invadopodia provide an elegant way for tumor cells to precisely couple focal matrix degradation with directional movement. Here we discuss several key components and regulators of invadopodia that have been uniquely implicated in tumor invasion and metastasis. Furthermore, we discuss existing and new therapeutic opportunities to target invadopodia for anti-metastasis treatment.
INTRODUCTION
Metastasis, the spread of tumor cells from a primary tumor to a secondary site, is a complex, multistep process, and is the main cause of mortality in cancer patients. During metastasis, carcinoma cells invade the surrounding extracellular matrix (ECM), intravasate through endothelium into the systemic circulation, then extravasate again through the capillary endothelium and finally establish secondary tumors at distant sites. 1 Several key stages of metastasis, including invasion, intravasation and extravasation, are thought to involve ECM degradation and remodeling. In recent years, actin-rich subcellular protrusions known as invadopodia have been shown to be critical for ECM degradation. 2 Invadopodia consist of an actin-rich core surrounded by a number of important protein components, including cytoskeletal modulators, adhesion proteins, scaffolding proteins and signaling molecules. 3 The central function of invadopodia is to recruit various matrix proteases to cell-ECM focal contacts for matrix degradation.
Unlike other actin-based protrusions such as lamellipodia and filopodia that are present in normal cells, invadopodia are uniquely present in invasive cancer cells and are considered as the transformed version of podosomes, which are present in highly invasive normal cells such as macrophages, osteoclasts and dendritic cells. In-depth reviews have covered all the molecular components of podosomes/invadopodia and their biological functions in development and pathogenesis. 3 This review focuses on a selective set of invadopodia components and regulators that are relatively unique to invadopodia and are specifically modulated in human cancers ( Figure 1 , Table 1 ). In addition, we will discuss the contributions of these invadopodia components to invasion and metastasis, and the therapeutic opportunities to target these components for cancer treatment.
STRUCTRUAL COMPONENTS
As an actin-based structure, invadopodia engage a large number of structural and regulatory proteins that control actin dynamics, such as Arp2/3, Enabled (Ena)/vasodilator-stimulated phosphoprotein (Vasp) and various small GTPases. Here we discuss three factors, cortactin, MENA and Tks proteins, that have critical roles at invadopodia and have been implicated in tumor progression. Cortactin and MENA are both key factors of actin polymerization and dynamics; therefore, their roles in tumor invasion and metastasis go beyond invadopodia to general cell migration and other actin-based cellular processes. In contrast, Tks proteins are known to be more specifically involved in invadopodia formation, therefore their impact on tumor invasion and metastasis is thought to be largely because of their functions at invadopodia.
Cortactin
Cortactin is a cytoskeletal protein that when phosphorylated can recruit the Arp2/3 complex to promote invadopodia formation. Cortactin was originally identified as a Src phosphorylation target in Src-transformed chicken embryo fibroblasts. 4 Src binds to cortactin through direct interaction with the SH2 domain of Src, 5 and phosphorylates cortactin in v-Src-transformed 3T3 fibroblasts. 4, 6 As Src kinase has an essential role in invadopodia regulation (discussed in detail in a later section), cortactin has been shown to be a key regulator of actin polymerization at invadopodia in response to Src activation. The association of cortactin with invadopodia was first described in MDA-MB-231 cells, in which microinjection of anti-cortactin antibodies reduced their ability to degrade ECM. 7 Furthermore, immunoprecipitation of cortactin revealed its presence in invadopodia-enriched membrane fractions. 7 Finally, immunofluorescence indicated cortactin at actively degrading invadopodia. 7, 8 Knockdown of cortactin in MDA-MB-231 cells resulted in inhibition of actin/cortactin-positive puncta and matrix degradation, suggesting that cortactin is required for invadopodia formation and function. 8 Cortactin localization at invadopodia coincided with phosphotyrosine puncta, which is consistent with Src regulation of cortactin phosphorylation. 9 Src activation of cortactin resulted in the localization of Nck1 and N-WASP at invadopodia, in addition to the disengagement of cofilin, all of which are required for Arp2/3-mediated actin polymerization to promote invadopodia formation. 10, 11 As cortactin regulates various actin-based cellular programs, including invadopodia and lamellipodia formation and dynamics, its role in tumor cell invasion and metastasis is well documented. Overexpression of cortactin in NIH3T3 cells resulted in increased invasion in a Matrigel Boyden chamber assay. 12 Similarly, overexpression of cortactin in MDA-MB-231 cells resulted in increased invasion, which correlated with increased metastatic bone lesions. 13 In contrast, overexpression of a phosphorylationdeficient cortactin inhibited invasion and resulted in minimal bone metastatic lesions. 13 Similar results were obtained in a hepatocellular carcinoma model, where overexpression of wildtype cortactin in the non-metastatic hepatocellular carcinoma cell line KIM1 increased metastatic incidence without affecting primary tumor growth. 14 Cortactin was first implicated in the progression of human cancers through gene amplification at chromosome 11q in breast and squamous cell carcinomas. 13, 15, 16 In addition, high levels of cortactin expression are also observed in human ovarian, bladder and lung cancer. 4, 7, 13, 15 Importantly, overexpression of cortactin is associated with poor patient prognosis in breast and head and neck squamous carcinomas, further highlighting a critical role of cortactin in human tumor progression. 13, 16 MENA Mena is a member of the Enabled (Ena)/VASP family of proteins, which are involved in the regulation of actin polymerization. Mena protein is upregulated in breast, pancreatic, colon, gastric, cervical cancers and melanoma, with the expression of specific isoforms regulating the invasive properties of breast cancer cells. [17] [18] [19] Owing to its role in actin polymerization, Mena is a logical regulator of invadopodia formation. Mena was found to co-localize with cortactin and F-actin at invadopodia. 18 In addition, Mena-null mouse mammary tumor virus-polyoma middle T (MMTV-PyMT) mammary tumors exhibited reduced invasion into the surrounding stroma. 20 In conjunction, Mena-null mice had significantly fewer circulating tumor cells and lung metastases, when compared with control mice, suggesting that Mena expression is necessary for tumor cell intravasation and invasion. 20 Interestingly, gene profiling in rat MTLn3 and mouse PyMT breast tumors identified an invasion-specific isoform of Mena, called Mena INV , whose expression was correlated with invasive ability. 17 Mena INV increased invasion of MTLn3 cells into collagen gels, indicating a unique role for Mena INV in carcinoma cell invasion. 18 In addition, MtLn3 cells expressing Mena INV exhibited increased membrane protrusions compared with parental MTLn3 cells. 18 In terms of metastatic progression, Mena INV expression was associated with highly metastatic carcinomas in the PyMT mouse mammary tumor model. 21 Philippar et al. 18 also observed that overexpression of Mena INV in MTLn3 cells resulted in increased micrometastatic lung formation, despite no effect on primary tumor growth, again indicating the importance of regulating Mena mRNA splicing in tumor invasion and metastasis. 20 Tks adaptor proteins The Tks adaptor proteins Tks4 and Tks5 are named after tyrosine kinase substrate with 4 or 5 SH3 domains, respectively. Tks proteins only contain SH3 and PH domains for protein-protein and protein-lipid interactions; therefore they are thought to serve as adaptor proteins that recruit other proteins and lipids 22 for invadopodia assembly. Figure 1 . An overview of the invadopodia components and regulators discussed in this review. Twist1-induced expression of PDGFRa leads to increased Src kinase activity, which serves as a trigger for invadopodia formation. Src-mediated phosphorylation of the structural components cortactin and Tks5, and the Arg/Abl tyrosine kinase promotes invadopodia assembly. Integrin b1 serves as an adhesion mediator between invadopodia and ECM, an activator of Abl/Arg at invadopodia, a sensor of matrix stiffness to regulate invadopodia assembly and a potential docking site for FAPa. Structural components of invadopodia, which include the actin core, are labeled in blue, proteases are labeled in purple and regulatory components are labeled in green.
The role of Tks5 in invadopodia was first discovered using a Src substrate screening assay, and further characterized based on its localization to invadopodia in Src-transformed fibroblasts. 23 Tks5 is required for both invadopodia formation and invasion activity in a variety of human cancer cell lines, as knocking down Tks5 reduced matrix degradation activity and invasion. 24 Likewise, introduction of Tks5 into the human breast epithelial cell line T47D, which lacks endogenous Tks5 expression, promoted invadopodia formation. 23 Tks5 was shown to bind to ADAM12 (A Disintegrin And Metalloproteinase), 25 a metalloproteinase associated with invadopodia. Furthermore, Tks5 is also associated with the actin regulatory protein N-WASP, 26 and involved in the recruitment of AFAPA-110, p190RhoGAP and cortactin to invadopodia. 27 Finally, Tks5 binds to p22 phox , a part of the NADPH oxidase complex that generates reactive oxygen species, that facilitates invadopodia assembly and function. 28 The family member Tks4 also localizes to invadopodia in Srctransformed cells and is required for invadopodia assembly. 29 However, Tks4 and Tks5 seem to have non-redundant roles in invadopodia function. Cells lacking Tks4 formed actin puncta resembling invadopodia, but these cells failed to degrade ECM components, even in the presence of high levels of Tks5. 29 This is thought to be because of a crucial role of Tks4 in recruiting MT1-matrix metalloproteinase (MMP) to invadopodia, as no MT1-MMP was detected in the rudimentary invadopodia present in Tks4 knockdown cells. 29 To test the role of Tks5 in tumor metastasis, Eckert et al. 24 showed that knocking down Tks5 in Ras-transformed human mammary epithelial cells that overexpress Twist1 inhibited both local invasion and the ability of these cells to form lung metastases, whereas primary tumor formation rates were not altered. These data strongly indicate that Tks5, and likely its role in invadopodia assembly, is required for the early steps of metastasis. To test whether Tks5 functions during extravasation and metastatic outgrowth, Blouw et al. 30 injected Src-transformed 3T3 cells with Tks5 knockdown into immunocompromised mice via tail vein. Although Tks5 knockdown did not significantly affect the number of lung colonies, the metastases derived from the cells with Tks5 knockdown were significantly smaller. These data suggest that Tks5 could be further required for the expansion of secondary tumors in distant sites.
PROTEASES
Given their central function to recruit proteases to cell-matrix contacts for matrix remodeling, invadopodia are shown to contain a large numbers of proteases. The proteases found at invadopodia include metalloproteases (both secreted and membrane-tethered MMP), the ADAM family members and membrane-bound serine proteases, all of which have been implicated in cancer progression and metastasis. Past research has focused on developing metalloproteinase inhibitors to suppress ECM degradation and tumor metastasis. Although these inhibitors show promising results in cell culture and tumor xenograft models, numerous metalloproteinase inhibitors have failed during clinical trials. 31 Further studies indicate that some metalloproteinases could have antitumorigenic effects. 32 Therefore, the strategy of broadly blocking metalloproteinases to abrogate metastasis might not be a viable approach to prevent tumor metastasis. Here we discuss a few proteases that are unique to invadopodia and might be promising new targets in inhibiting tumor invasion and metastasis.
Metalloproteinases MT1-MMP. MT1-MMP (also known as MMP14), a membraneanchored metalloproteinase, is considered a central factor of invadopodia-mediated ECM degradation. MT1-MMP cleaves 33 several substrates in vitro, including ECM components such as fibronectin, type I, II and III collagen, laminins, vitronectin and aggrecans. [34] [35] [36] [37] In addition, MT1-MMP is capable of activating other MMP zymogens: MT1-MMP activates MMP2 by cleaving the N-terminal prodomain of pro-MMP2 38 and MMP9 is activated through an activation cascade involving MT1-MMP, MMP2 and MMP3.
39 MT1-MMP is shown to be required for the matrix degradation activity of invadopodia. Artym et al. 8 found that cortactin aggregation initiated accumulation of MT1-MMP at invadopodia. This study also found that although MT1-MMP knockdown moderately impacted the initial stages of invadopodia formation, matrix degradation was strongly suppressed, 8 indicating that MT1-MMP is essential for functional invadopodia.
MT1-MMP is delivered to invadopodia by multiple routes. Studies from Yu et al. 40 show that N-WASP, which promotes actin nucleation, promotes the delivery of MT1-MMP from late endosomes to invadopodia.
41 MT1-MMP can also be mobilized by the Rab8-dependent secretory pathway and delivered to collagen-contact sites. 42 Finally, MT1-MMP can also be internalized by both clathrin-and caveolae-mediated endocytosis, 3, 43 and this internalization serves to recycle MT1-MMP back to invadopodia when needed.
A key inducer of invadopodia, Src kinase, has also been shown to directly regulate the delivery of MT1-MMP to invadopodia. Srcmediated phosophorylation of MT1-MMP in its AP2 clathrin adaptor binding domain slows endocytosis of MT1-MMP and increases matrix degradation activity. 43 In addition, phosphorylation of MT1-MMP by Src at Tyr573 has been shown to be required for tumor cell proliferation, invasion of threedimensional (3D) collagen matrices and tumor growth in nude mice. 44, 45 Finally, a recent study found that this phosphorylation was required for mono-ubiquitination of Lys581, which is involved in MT1-MMP trafficking to the cell surface and cellular invasion through collagen matrices. 46 An increase in MT1-MMP expression is generally associated with poor prognosis in a wide variety of human cancers, including breast, lung, melanoma, colorectal and squamous cell carcinomas.
47 MT1-MMP expression has also been directly linked to metastasis in mouse tumor models. MT1-MMP-deficient mice were bred with MMTV-PyMT mice, and then PyMT-positive mammary glands lacking MT1-MMP were orthotopically transplanted into wild-type mice. Although palpable tumors developed faster with MT1-MMP-deficient mammary glands, metastatic spread was reduced by 50%. 48 Consistent with this study, Perentes et al. 49 injected MDA-MB-231 cells with MT1-MMP knockdown into the mammary fad pad of severe combined immunodeficiency (SCID) mice and found that MT1-MMP knockdown resulted in a significant decrease in lung metastasis without affecting primary tumor growth. 49 These results suggest that MT1-MMP is required for metastatic development in vivo.
As blocking MMP activity has failed in clinical trials as an antimetastasis therapy, possibly due to the broad spectrum of inhibition and severe toxicities, 50, 51 new therapeutic strategies aim to target the specific MMPs that contribute to disease progression. 50 A fully humanized monoclonal antibody (DX-2400, Dyax Corporation) that targets MT1-MMP at its catalytic domain showed great promise in preclinical studies. DX-2400 abrogated MMP2 cleavage on tumor and endothelial cells, blocked angiogenesis, and reduced tumor formation and metastasis. 50, 52 Another humanized antibody targeting the non-catalytic hemopexin domain of MT1-MMP has recently shown promise in inhibiting invasion and angiogenesis in preclinical studies. 53 The therapeutic potential of targeting MT1-MMP to inhibit invadopodia-mediated tumor invasion and metastasis holds great future promise.
ADAM proteases
The ADAMs are a family of disintegrin and metalloproteinases that are involved in a variety of biological processes, including cell
The role of invadopodia in tumor metastasis H Paz et al adhesion, migration, proteolysis, myoblast fusion and fertilization. 54 Here, we focus on ADAM12 because of its more established presence at invadopodia. ADAM12 has two alternatively spliced variants: ADAM12-L, which consists of pro-, metalloprotease, disintegrin, cysteine-rich, transmembrane and cytoplasmic domains, and ADAM12-S, which lacks the transmembrane and cytoplasmic domains. 55 ADAM12 contributes to invadopodia function at multiple levels, including degrading the ECM, modulating integrin function, and functioning as a sheddase to activate growth factors. 56 ADAM12 is localized to invadopodia, binds to the scaffold protein Tks5 25 and has been found to trigger invadopodia assembly. 57 The sheddase activity of ADAM12 may contribute to the overall degradation activity of invadopodia. A recent study by Diaz et al. 58 demonstrated that ADAM12 expression was elevated in a Notch-dependent manner under hypoxic conditions. ADAM12 promoted the ectodomain shedding of heparin-binding epidermal growth factor (EGF)-like growth factor, which in turn induced invadopodia formation and the invasive activity of cancer cells. 58 ADAM12 is implicated in a variety of cancers, including breast, prostate, lung, liver, brain and bone cancers, as well as aggressive fibromatosis. 59 In human breast cancer patients, Roy et al.
60
showed that ADAM12 is a prognostic marker, as urinary levels of ADAM12 increased along with disease stage. Transgenic mice expressing the ADAM12-S isoform driven by the MMTV-LTR promoter were bred with mice carrying the PyMT oncogene in the mammary gland; PyMT expression in the mammary gland led to rapid formation of mammary carcinomas. Tumors in mice expressing ADAM12-S developed faster than in littermates expressing PyMT alone. 61 Similarly, the ADAM12-S isoform significantly increased the ability of MCF-7 cells to migrate and invade, which led to a higher incidence of local and distant metastases in vivo. 62 Interestingly, cells expressing a catalytically dead mutant of ADAM12-S failed to promote tumor development, indicating that the proteolytic activity of ADAM12-S is required to promote formation of distant metastases. 62 Serine proteases Two transmembrane type II serine proteases of the dipeptidylpeptidase (DPP) family, fibroblast activation protein (FAP; FAPa, also known as seprase) and DPP4, have also been associated with invadopodia. Both DPP4 and FAPa contain exopeptidase activity, and FAPa also exhibits endopeptidase activity. 63, 64 Previous studies have shown that FAPa is localized at invadopodia as a complex with DPP4 65 or, alternatively, associated with a3b1 integrin, with the integrin serving as a docking site for FAPa. 66 The role of FAPa in invadopodia is currently unclear, but some studies suggest that its gelatinase activity may contribute to the overall degradation activity of invadopodia. Christiansen et al. 67 found that FAPa digests collagen I into smaller fragments following initial cleavage by MMP-1, suggesting that FAPa works together with other proteases to cleave partially degraded ECM components.
A key difference between FAPa and DPP4 is that expression of DPP4 is ubiquitous throughout all tissues, whereas that of FAPa is restricted to tissues undergoing wound healing and epithelial cancers, 64, 68 thus making FAPa a unique factor in tumor progression. Indeed, FAPAa has been shown to be expressed in a variety of aggressive cancers, including breast, colon and ovarian cancers, and malignant melanoma. 69 In addition, genetic deletion of FAPa inhibited tumor growth in a K-ras-driven model of endogenous lung cancer and in a mouse model of colon cancer. Pharmacological inhibition of FAPa also attenuated tumor growth in these mouse models, indicating that FAPa is a promising target for therapeutic intervention. 70 In human and mouse tumors, FAPa has been shown to be expressed in stromal fibroblasts, carcinoma cells and immune cells. 69, [71] [72] [73] What remains to be answered is whether and how FAPa in individual cell types contributes to tumor progress, and whether the role of FAPa at invadopodia is critical for tumor invasion and metastasis. Previous attempts to target FAPa for therapeutic intervention have proven to be challenging. In 2003, Phase I/II clinical trials for the humanized FAPa monoclonal antibody Sibrotuzumab failed to demonstrate measurable therapeutic activity in patients with metastatic colorectal cancer, 74 with only 2 out of 17 patients having stable disease during the Phase II trial. 74 However, this antibody has not been shown to block any cellular or protease function of FAPa, which might explain the lack of therapeutic effects. In 2007, a small molecule inhibitor of FAPa, Talabostat, was developed to inhibit the protease activity of FAPa. Again, minimal clinical activity was observed in patients with metastatic colorectal cancer receiving Talabostat alone, 75 or in metastatic melanoma patients receiving Talabostat in conjunction with cisplatin treatment. 76 However, the stability of this inhibitor in vivo is thought be extremely poor, thus limiting its effectiveness.
Given these recent setbacks in targeting FAPa, efforts have recently turned to FAPa-mediated immunotherapy. One approach is to develop DNA vaccines to target FAPa, thus eliminating all FAPa-positive cell types in a tumor. Several groups reported that through CD8 þ T-cell-mediated killing, such therapy successfully suppressed primary tumor cell growth and metastasis of implanted breast and colon tumors without obvious toxicity. 77, 78 Another approach is to deliver radioisotopes specifically to the tumor site using FAPa antibodies as cargoes. Preclinical studies involving two humanized FAPa monoclonal antibodies (ESC11 and ESC14) labeled with the radiolanthanide 177 Lu have yielded promising results: both antibodies accumulated in human FAPa-positive xenografts and delayed tumor growth. 79 Given that FAPa is expressed in various cell types in a tumor, it is important to recognize that the effect of targeting FAPa on tumor progression cannot solely be explained by inhibition of invadopodia. However, these results suggest a unique approach to targeting components of invadopodia in human cancers.
REGULATORY COMPONENTS
As ECM is essential for cell survival and proliferation, invadopodiamediated matrix degradation is a highly regulated process. Understanding the upstream inducing signals of invadopodia formation and function is still in its infancy. A significant number of signaling regulators, including EGFR, PDGFR, PI3 kinase (epidermal growth factor receptor, platelet-derived growth factor receptor, and phosphoinositide 3, respectively) and c-Met have been implicated in invadopodia regulation in various cancer cell lines. As many of them have critical roles in multiple cellular processes in cancer, including cell proliferation and apoptosis, it is difficult to attribute their functional impact on tumor progression specifically to invadopodia. Therefore, here we discuss a few key upstream signaling pathways that have been more uniquely implicated in invadopodia function during tumor progression and metastasis.
Phosphorylation via Src and Arg tyrosine kinases Tyrosine phosphorylation of many core components is critical to trigger invadopodia assembly and function. Especially, two tyrosine kinases, Src and Arg, stand out as essential activators of invadopodia.
Src kinase. The Src kinase is the founding member of the Src family of non-receptor tyrosine kinases, 80 of which, Src is the only family member that is uniquely linked to invadopodia. The role of Src in invadopodia formation was first described by Chen et al. 81 , where Rous sarcoma viral (RSV) transformation of chicken embryonic fibroblasts resulted in actin rosette or podosome
The role of invadopodia in tumor metastasis H Paz et al formation. In addition, RSV-mediated cellular transformation correlated with the appearance of pp60 Src accumulation at these rosettes. Similarly, invadopodia formation was enhanced with constitutive expression of active c-Src, as evidenced by colocalization of F-actin and cortactin staining. 82 In contrast, overexpression of a kinase-inactive c-Src and knockdown of c-Src by RNAi showed decreased invadopodia formation and degradation activities. 9, 83, 84 Closer examination of protrusion formation in MDA-MB-231 cells revealed that overexpressing wild-type Src or constitutively active Src exhibited invadopodia extension into the collagen gel. 9 Src kinase has been shown to have a major role in the invasive process. Expression of c-Src in SYF (src À / À , yes À / À , fyn À / À ) murine embryonic fibroblasts promoted invasion, whereas Ras V-12 failed to do so in a Boyden chamber assay. 85 Similarly, MDA-MB-231 breast cancer cells treated with Src small interfering RNAs exhibited reduced matrix degradation and invasion through matrix-coated chambers. 84 Treatment with Src inhibitors, Dasatinib, PP2 or SU6656, in MDA-MB-231 cells reduced invasion through Matrigel, indicating the importance of Src activity for tumor cell invasion into the ECM. 86 Although Src was originally isolated as an oncogene, recent studies suggest a more critical role for Src in tumor metastasis. 85, 87, 88 Specifically, c-Src activity is correlated with increased bone metastases, poor clinical prognosis and reduced survival for breast and colon carcinoma patients. 86, 89, 90 Src gene deletion in MMTV-PyMT mammary tumor models resulted in a reduction in circulating tumor cells, despite no defect in primary mammary tumor initiation and proliferation. 91 Similarly, Src small interfering RNA-treated L3.6pl pancreatic cancer cells exhibited a reduction in lung and liver metastasis. 92 c-Src was required for formation of metastatic lung colony formation by H-Ras V-12 expressing SYF (src À / À , yes À / À , fyn À / À ) murine embryonic fibroblast cells, supporting the role of Src in tumor progression. 85 Likewise, BoM-1833, a bone metastatic derivative of MDA-MB-231 cells, which were injected into recipient mice, showed increased survival and reduced bone metastases upon treatment with Src small interfering RNA. 89 As Src activity has a prominent role in cancer progression, it is an ideal therapeutic target. The Src selective inhibitor, SU6656, has been found to inhibit Src kinase activity, as evidenced by reduced levels of phospho-Y418-Src. SU6656 was also found to significantly reduce invadopodia formation, as well as migration and invasion of the human breast cancer line MDA-MB-231. 82 KX2-391 is a firstin-class Src selective inhibitor undergoing clinical trial that targets the unique Src substrate binding site. 93 KX2-391 has shown promising preclinical data, with KX2-391 treatment in combination with paclitaxel resulting in the regression of pre-established MDA-MB-231 xenograft tumors. 94 In addition, KX2-391 treatment led to reduced metastasis formation of MDA-MB-231 tumors in the lung and liver. 94 Phase I trials in patients with solid tumors showed that KX2-391 is well tolerated and demonstrated preliminary antitumor activity, with several patients displaying halted disease progression. 95 Abl/Arg. Similar to Src kinase, the Abl family of non-receptor tyrosine kinases, which includes c-Abl and the Abl-related gene (Arg/Abl2), has an important role in tumor progression in human leukemia, non-small cell lung cancer, breast cancer, melanoma and pancreatic cancer. 96 Specifically, c-Abl and Arg kinase activities have been shown to correlate with poorly differentiated and highly invasive breast cancer lines. 97 The role of Abl/Arg kinase was initially hypothesized in invadopodia formation due to previously known activation of Abl by Src kinases. More specifically, PDGF and EGF stimulation of fibroblast and breast cancer cells resulted in c-Abl activity through Src and Fyn phosphorylation. 97, 98 Treatment of various highly invasive breast cancer cell lines with Src inhibitor SU6656 reduced c-Abl and Arg activity. 97 Src activation of Arg is required for cortactin phosphorylation and actin polymerization at invadopodia, as knockdown of Arg in MDA-MB-231 cells resulted in no cortactin phosphorylation and reduced F-actin barbed-end generation. 84 The Abl family of non-receptor tyrosine kinases has also been localized directly to the invadopodia structure. YFP-tagged wildtype and constitutively active Arg co-localized with cortactinpositive invadopodia in Src expressing NIH3T3 cells, whereas kinase-inactive Arg expression disrupted invadopodia formation. 99 Similarly, immunofluorescence staining of Arg in MDA-MB-231 cells showed co-localization with Tks5-positive invadopodia. 84 Abl and Arg kinases also have a significant role in tumor invasion and metastasis. Knockdown of Abl and Arg reduced the ability of MDA-MB-231, and its metastatic derivatives, to degrade ECM and invade. 97, 99 Inhibition of Abl kinase activity with STI571, an Abl/Arg inhibitor, reduced invasion of MDA-MB-435S breast cancer cells in a Matrigel invasion assay. 97 MDA-MB-231 cells expressing Arg and Abl small hairpin RNA constructs showed fewer circulating tumor cells in vivo compared with control tumorbearing mice. 100 Similarly, Gil-Henn et al. 100 showed that STI571-treated mice showed fewer circulating tumor cells compared with control mice bearing MDA-MB-231 tumors. These results indicate that Abl kinase activity is required for tumor cell intravasation.
A number of tyrosine kinase inhibitors with dual specificities toward Src and Abl family tyrosine kinases, including Dasatinib, Saracatinib, and Bosutinib, have been developed and showed promising activities against tumor invasion and metastasis in several solid tumors preclinical studies. Specifically, these inhibitors were found to significantly reduce invadopodia formation, as well as migration and invasion of the human breast cancer line MDA-MB-231. 86, 101, 102 In addition, treatment of mice with Dasatinib led to reduced formation of bone metastases by BoM-1833 cells. 89 Similar results have been observed in pancreatic tumors, with Dasatinib treatment leading to a reduction in primary tumor growth and metastasis formation by L3.6pl cells. 92 However, these inhibitors have shown limited activity in monotherapy trials. 93 It is important to note, however, that completed clinical trials studying the efficacy of Src/Abl inhibitors have been conducted in unselected cancer patients. Many ongoing trials using biomarkers (such as cortactin phosphorylation) to pre-select patients who are more likely to benefit from Src/Abl inhibition hold promise for the future success of Src/Able inhibitors in cancer treatment. 93 Integrin-mediated signaling Given that integrins are the key connection between cell protrusions and the surrounding ECM, it is not surprising that they have important roles in invadopodia regulation. Integrin clustering at invadopodia was first described in RSV transformation of chicken embryonic fibroblasts (RSVCEF). RSVCEFs cultured with fibronectin-coated beads exhibited invadopodia formation, which was associated with b1 staining. 103 Interestingly, fibronectin-positive vesicles were found to co-stain with b1 integrin; further validating the functional role of invadopodia in matrix degradation. 103 In contrast, murine embryonic fibroblasts overexpressing Src and depleted for b1 integrin exhibit reduced rosette formation. 104 In addition, treatment of SCC61 squamous cell carcinoma cells with an integrin blocking peptide or a b1 integrin blocking antibody led to a reduction in actively degrading invadopodia per cell. 105 Finally, knocking down b1 integrin in MDA-MB-231 and MTLn3 mammary adenocarcinoma cells led to a reduction in mature invadopodia formation. 106 How integrins regulate invadopodia function has not been clearly elucidated. Various studies indicate that integrins promote invadopodia maturation by serving as a docking station for various proteases and/or activating Arg kinase for actin stabilization. Laminin peptide activation of b1 integrin in lysyl oxidase The 107 due to increased seprase/FAPAa recruitment to invadopodia by binding to b1 integrin. 7, 107 More recently, b1 integrin has been found to activate Arg kinase. Fluorescence resonance energy transfer (FRET)-based experiments point to direct interaction between b1 integrin and Arg at Tks5-positive invadopodia. 106 Changes in integrin-mediated adhesion signaling complexes are known to have an important role in tumor cell proliferation, migration and survival. 108 Specifically, loss of b1 integrin in MMTVdriven Erb2 breast tumor mice reduced Y416 c-Src phosphorylation and metastatic lesion formation in the lungs. 109 Similarly, tail vein injection of MDA-MB-435 breast cancer cells expressing a constitutively active mutant avb3 exhibited enhanced metastatic lung colonization. 109 To date, it is unclear which integrin subunits are the predominant forms required for invadopodia function. As the focus of current integrin-targeted therapies has been on their anti-angiogenic properties, their potential as an anti-metastatic treatment by invadopodia inhibition requires identifying and targeting invadopodia-specific integrins in the near future.
Transcriptional regulation by EMT-inducing factors To detach from the primary tumor and invade through the surrounding tissue, carcinoma cells need to first break down cellcell junctions, become more motile, remodel cell-matrix adhesion sites and invade through the ECM. A developmental program termed epithelial-mesenchymal transition (EMT) enables tumor cells to obtain such properties. During EMT, cells need to co-ordinate the dissociation of cell-cell adhesions and the breakthrough of basement membrane to accomplish this complex morphogenetic event.
1 Recent studies indicate a critical role of invadopodia-mediated ECM degradation during EMT.
The EMT program is orchestrated by a group of transcription factors, all of which have been implicated in tumor invasion and metastasis. 110 Specifically, the basic helix-loop-helix (bHLH) transcription factor Twist1 was shown to have critical roles in tumor metastasis in both breast tumor xenografts and in mouse skin tumor models. 111, 112 Eckert et al. 24 found that Twist1 was required for ECM invasion by inducing the formation of invadopodia in human and mouse breast tumor cells. Twist1 was found to directly induce expression of PDGFRa, which then activates Src kinase to promote invadopodia formation. 24 Furthermore, blocking invadopodia formation by knocking down PDGFRa or Tks5 abolished the ability of Twist1 to promote tumor metastasis in mice. This study not only uncovers Twist1 as a novel upstream regulator of invadopodia formation, but also provides a direct link between invadopodia and metastasis.
Another potent inducer of EMT is transforming growth factor-b (TGFb). 1 TGFb promotes EMT by activation of extensive intracellular signaling that involves Smad proteins, ERK and Jagged/Notch signaling, among others. 113 Of particular interest in the context of invadopodia, Eckert et al. 24 showed that knocking down Twist1 blocked the ability of TGFb to induce PDGFRa and invadopodia formation. In addition, Pignatelli et al. 114 also demonstrated that Hic-5, a focal adhesion adaptor protein induced by TGFb, localized to invadopodia in TGFb-treated MCF-10A cells. They showed that Hic-5 was phosphorylated by Src kinase upon TGFb stimulation, and this phosphorylation was required for TGFb-induced invadopodia formation and invasion, thereby further emphasizing the role of EMT-inducing genes in invadopodia regulation.
Matrix stiffness and mechanoregulation Recent evidence has implicated matrix stiffness in tumor progression and increased incidence in metastasis through increased collagen deposition. [115] [116] [117] Several elegant studies show that increasing matrix stiffness without altering biochemical components of the ECM can induce a malignant phenotype, suggesting that mechanical force exerted by a stiff ECM could have a critical role in tumor invasion and metastasis. 118 In mice, LOX-mediated collagen cross-linking stiffens tumor ECM and promotes breast tumor progression. 119 Furthermore, inhibition of LOX blocks tumor invasion and eliminates metastasis formation from orthotopically grown breast tumors. 33 Indeed, ECM rigidity is indicated in invadopodia regulation. Specifically, Alexander et al. 120 noted that CA1d breast cancer cells plated on increasing concentrations of gelatin showed increased invadopodia formation and ECM degradation. Interestingly, two studies showed that both CA1d and 804G bladder cancer cells exhibited increased invadopodia formation when placed on matrix substrates with increasing mechanical rigidity without changing their biochemical components. 121 Furthermore, these studies showed that invadopodia-mediated ECM degradation only increased when placed on surfaces within the kPa range, which corresponds to the stiffness in tumors. 121 Although it is not well understood how matrix rigidity regulates invadopodia formation, this study suggests that activation of p130Cas and FAK by myosin II, which acts as mechanosensors that transmit mechanical signals from ECM, could have a prominent role. 120 Given the effects of increasing matrix stiffness on invadopodia functions, it is possible that mechanical forces generated by rigid tumor matrix stiffness could modulate invadopodia function to impact tumor progression and metastasis.
THE ROLE OF INVADOPODIA IN TUMOR INVASION AND METASTASIS
The critical role of invadopodia in ECM degradation explains why the ability to form invadopodia largely correlates with the invasive and metastatic potential of tumor cells. 122 Suppressing invadopodia formation by inhibiting Src, Twist1 or Tks5 has been convincingly shown to inhibit tumor metastasis in various tumor models. Invadopodia could have critical roles during three steps of the metastatic process: invasion into the surrounding stroma, intravasation into the vasculature and extravasation (Figure 2 ). Direct in vivo visualization and assessment of invadopodia formation during the metastatic process has proven to be challenging because of the limited numbers of invadopodiaspecific markers in a 3D microenvironment. Furthermore, it remains unclear whether actin-based protrusions observed in two-dimensional culture, including filopodia and invadopodia, share similar components or merge into one structure in 3D; thus confusing the issue of defining invadopodia in vivo.
New imaging techniques have made it possible to begin to identify invadopodia-like protrusions in vivo (Figure 2 ). Using 3D time-lapse imaging, Gligorijevic et al. 123 observed protrusion formation by MTLn3 rat mammary adenocarcinoma xenograft tumors growing in the mammary fat pad of SCID mice. These protrusions were positive for cortactin and proteolytic activity, as evidenced by cleaved collagen 3/4 staining, indicating the presence of invadopodia in vivo. Looking specifically at the intravasation, Gligorijevic et al. 123 used the photoconvertible Dendra2 protein to trace tumor cell intravasation in vivo. Control MTLn3 primary tumor cells were shown to disappear from the imaging area due to dissemination of cells into the blood stream. In contrast, knocking down N-WASP resulted in no visible dissemination. Yamaguchi et al. 124 observed similar invadopodia-like protrusions during tumor cell intravasation using intravital imaging. Green fluorescent protein (GFP) expressing MTLn3 cells revealed invadopodia-like protrusions extending into the blood vessel wall. These invadopodia-like protrusions were shown to help tumor cells to penetrate the ECM surrounding the blood vessel walls and to squeeze through the endothelial barrier. 124 Together, these data strongly support the notion that invadopodia are required for tumor cell intravasation (Figure 2 ).
The role of invadopodia in tumor metastasis H Paz et al Assessment of invadopodia formation during the extravasation process is more limited; however, protrusive structures have been identified by actively extravasating tumor cells. 125, 126 Specifically, time course observations of intra-meseneric vein injection of GFP-positive rat tongue carcinoma cells reveal clusters of tumor cells in the sinusoids. 125 Over time, the authors noted focal loss of basement membrane at sinusoidal areas where extravasation was taking place. 125 The loss of basement membrane indicates potential sites of active ECM degradation by invadopodia. Protrusive structures have also been identified by actively extravasating MDA-MB-435 cells expressing Twist1 upon injection into the vasculature of zebrafish. 126 Direct imaging of tumor cells in the vasculature revealed that Twist1-overexpressing cells display large, rounded protrusions, 126 suggesting that invadopodia-like protrusions by extravasating tumor cells contribute to ECM degradation and breaking through the endothelium barrier ( Figure 2 ).
FUTURE DIRECTIONS AND THERAPEUTIC IMPLICATIONS
As discussed, recent progress suggests an essential role of invadopodia in tumor invasion and metastasis. The specific presence of invadopodia in invasive tumor cells and their unique ability to precisely co-ordinate localized ECM degradation with cell movement make them ideal targets for anti-metastasis therapies.
A number of critical issues need to be resolved to put invadopodia at the forefront of tumor metastasis research and treatment. First, although actin assembly and elongation during invadopodia initiation have been extensively studied, it remains unclear what and how matrix degrading enzymes are recruited to invadopodia to perform their functions. As broad inhibition of MMPs has not been successful in blocking metastasis, the strategy to inhibit protease recruitment could be a promising new route to specifically target ECM degradation and tumor invasion. Second, it remains unclear whether and how the molecular components and regulation of invadopodia and other actin-based membrane protrusions are different. As many invadopodia components have critical roles in various cellular processes, such as proliferation, apoptosis and migration, it is difficult to attribute all their observed activities on tumor progression to invadopodia function. Understanding such differences would further solidify the unique role of invadopodia in tumor metastasis in vivo and lead to more specific targeting therapies against invadopodia in tumors without affecting normal cellular functions.
To move invadopodia inhibitors into therapeutic applications against tumor metastasis, we first need to determine how to apply invadopodia inhibitors for cancer treatment. As discussed, the main function of invadopodia in tumors is to promote matrix degradation and tumor invasion, but not to regulate cell proliferation or survival. Therefore, the main utility of invadopodia inhibitors should be to prevent primary and secondary metastasis occurrences, instead of inhibiting the growth of established primary tumors and metastases. Invadopodia inhibitors could be beneficial in preventing new metastasis development in a number of metastasis-prone cancer patient groups. Using breast cancer as an example, a group of cancer patients who have already developed limited metastatic diseases, such as a single brain metastasis, may use invadopodia inhibitors to prevent secondary metastasis lesions in the brain. Also, patients that have presented lymph node positivity could benefit from invadopodia inhibitors to prevent distant metastasis development. Furthermore, recent gene expression profiling and biomarker studies make it possible to predict long-term metastasis occurrence and survival outcome in early-stage breast cancer patients. Invadopodia inhibitors, in combination with traditional chemotherapies, could potentially reduce metastasis development in a selected high-risk patient population based on such molecular profiling.
Another pressing issue that faces the entire metastasis field, including invadopodia research, is how to develop proper clinical trials to test anti-metastatic agents such as invadopodia inhibitors. As discussed above, invadopodia mainly function to promote matrix degradation, thus perturbation of their functions in tumors have little or no effect on tumor proliferation. Unfortunately, the current clinical trial system requires all anti-cancer agents to show efficacy in phase II by shrinking established primary tumors and/or distant metastases in patients before moving to phase III trials and regulatory approval. Only after approval can these agents be tested in metastasis prevention trials for more early-stage cancer patients. As invadopodia-specific inhibitors are unlikely to shrink existing tumors and metastases, these inhibitors would fail in Figure 2 . The role of invadopodia in metastasis progression. Tumor metastasis takes place in a series of steps: invasion into the surrounding stroma (a), intravasation into the vasculature (b), extravasation out of the vasculature (c) and colonization at distant sites. Given that invadopodia function to degrade ECM, invadopodia are thought to have critical roles during various steps of metastasis (a-c).
current phase II clinical trials even though they might be potent to prevent new metastasis occurrence. A stimulating article by Dr PS Steeg 127 has proposed that the rate of new metastasis occurrence in metastasis high-risk patients as a more appropriate end point for metastasis prevention trials. Given the unique role of invadopodia in tumor invasion and metastasis, invadopodia inhibitors need to be tested in better-designed metastasis prevention trials to explore their full potential in combating tumor metastasis.
